Poster Presentation BACPATH 2017

Inhibition of diverse DsbA enzymes in multi-DsbA encoding pathogens (#117)

Rabeb Dhouib 1 , Dimitrios Vagenas 1 , Jason J. Paxman 2 , Tony Wang 2 , Pooja Sharma 3 , Jennifer L. Martin 4 , Martin J. Scanlon 3 , BegoƱa Heras 2 , Makrina Totsika 1
  1. Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia
  2. Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, Australia
  3. Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia
  4. Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia

DsbA catalyses disulfide bond formation in secreted and outer membrane proteins in bacteria. In pathogens, DsbA is a major facilitator of virulence constituting a target for antivirulence antimicrobial development. However, many pathogens encode multiple and diverse DsbA enzymes for virulence factor folding during infection. Here we investigated whether our recently identified inhibitors of Escherichia coli K-12 DsbA can inhibit the diverse DsbA enzymes found in two important human pathogens and attenuate their virulence.

DsbA inhibitors from two chemical classes (phenylthiophene and phenoxyphenyl derivatives) inhibited the virulence of uropathogenic Escherichia coli (UPEC) and Salmonella enterica serovar Typhimurium, encoding two and three diverse DsbA homologues, respectively. Inhibitors blocked the virulence of dsbA null mutants complemented with structurally diverse DsbL and SrgA, suggesting they were not selective for prototypical DsbA. Structural characterisation of DsbA-inhibitor complexes showed that compounds from each class bind in a similar region of the hydrophobic groove adjacent to the CPHC active site. Modelling of DsbL- and SrgA-inhibitor interactions showed that these accessory enzymes could accommodate the inhibitors in their different hydrophobic grooves, supporting our in vivo findings. Furthermore, we identified highly conserved residues surrounding the active site for 20 diverse bacterial DsbA enzymes, which could be exploited in developing inhibitors with a broad-spectrum of activity.

In conclusion, we have developed tools to analyse the specificity of DsbA inhibitors in bacterial pathogens encoding multiple DsbA enzymes. This work demonstrates that DsbA inhibitors can be developed to target diverse homologues found in bacteria.